149 related articles for article (PubMed ID: 35974065)
1. In-vivo pharmacokinetic studies of Dolutegravir loaded spray dried Chitosan nanoparticles as milk admixture for paediatrics infected with HIV.
K PD; D RD; S B; B Narayanan VH
Sci Rep; 2022 Aug; 12(1):13907. PubMed ID: 35974065
[TBL] [Abstract][Full Text] [Related]
2. pH-sensitive chitosan nanoparticles loaded with dolutegravir as milk and food admixture for paediatric anti-HIV therapy.
Priya Dharshini K; Fang H; Ramya Devi D; Yang JX; Luo RH; Zheng YT; Brzeziński M; Vedha Hari BN
Carbohydr Polym; 2021 Mar; 256():117440. PubMed ID: 33483020
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Solubility and Bioavailability of Dolutegravir by Solid Dispersion Method: In Vitro and In Vivo Evaluation-a Potential Approach for HIV Therapy.
Chaudhary S; Nair AB; Shah J; Gorain B; Jacob S; Shah H; Patel V
AAPS PharmSciTech; 2021 Apr; 22(3):127. PubMed ID: 33835317
[TBL] [Abstract][Full Text] [Related]
4. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
[TBL] [Abstract][Full Text] [Related]
5. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744.
Ford SL; Gould E; Chen S; Margolis D; Spreen W; Crauwels H; Piscitelli S
Antimicrob Agents Chemother; 2013 Nov; 57(11):5472-7. PubMed ID: 23979733
[TBL] [Abstract][Full Text] [Related]
6. Production of a new platform based on fumed and mesoporous silica nanoparticles for enhanced solubility and oral bioavailability of raloxifene HCl.
Varshosaz J; Dayani L; Chegini SP; Minaiyan M
IET Nanobiotechnol; 2019 Jun; 13(4):392-399. PubMed ID: 31171744
[TBL] [Abstract][Full Text] [Related]
7. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
Waitt C; Orrell C; Walimbwa S; Singh Y; Kintu K; Simmons B; Kaboggoza J; Sihlangu M; Coombs JA; Malaba T; Byamugisha J; Amara A; Gini J; Else L; Heiburg C; Hodel EM; Reynolds H; Mehta U; Byakika-Kibwika P; Hill A; Myer L; Lamorde M; Khoo S
PLoS Med; 2019 Sep; 16(9):e1002895. PubMed ID: 31539371
[TBL] [Abstract][Full Text] [Related]
8. Dolutegravir response in antiretroviral therapy naïve and experienced patients with M184V/I: Impact in low-and middle-income settings.
Ndashimye E; Arts EJ
Int J Infect Dis; 2021 Apr; 105():298-303. PubMed ID: 33722682
[TBL] [Abstract][Full Text] [Related]
9. Is resistance to dolutegravir possible when this drug is used in first-line therapy?
Mesplède T; Wainberg MA
Viruses; 2014 Aug; 6(9):3377-85. PubMed ID: 25166745
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
Nickel K; Halfpenny NJA; Snedecor SJ; Punekar YS
BMC Infect Dis; 2021 Feb; 21(1):222. PubMed ID: 33637050
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis/mycobacterium avium complex.
Le X; Guo X; Sun J; Liu L; Shen Y; Wang J; Qi T; Wang Z; Tang Y; Song W; Yin L; Zhang L; Zhang R; Chen J
Int J Infect Dis; 2022 Mar; 116():147-150. PubMed ID: 34999246
[TBL] [Abstract][Full Text] [Related]
12. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
Girouard MP; Sax PE; Parker RA; Taiwo B; Freedberg KA; Gulick RM; Weinstein MC; Paltiel AD; Walensky RP
Clin Infect Dis; 2016 Mar; 62(6):784-91. PubMed ID: 26658053
[TBL] [Abstract][Full Text] [Related]
13. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
Santevecchi BA; Miller S; Childs-Kean LM
Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
[TBL] [Abstract][Full Text] [Related]
14. Expanding the use of dolutegravir-based antiretroviral therapy in multidrug-resistant TB.
Murphy RA; Douglas-Jones B; Mucinya G; Sunpath H; Govender T
Int J Tuberc Lung Dis; 2021 Sep; 25(9):696-700. PubMed ID: 34802490
[TBL] [Abstract][Full Text] [Related]
15. Saliva as a potential matrix for evaluating pharmacologically active dolutegravir concentration in plasma.
Yamada E; Takagi R; Moro H; Sudo K; Kato S
PLoS One; 2021; 16(2):e0246994. PubMed ID: 33600473
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial.
Sculier D; Wandeler G; Yerly S; Marinosci A; Stoeckle M; Bernasconi E; Braun DL; Vernazza P; Cavassini M; Buzzi M; Metzner KJ; Decosterd LA; Günthard HF; Schmid P; Limacher A; Egger M; Calmy A;
PLoS Med; 2020 Nov; 17(11):e1003421. PubMed ID: 33170863
[TBL] [Abstract][Full Text] [Related]
17. Ultra-long acting prodrug of dolutegravir and delivery system - Physicochemical, pharmacokinetic and formulation characterizations.
Khuroo T; Dharani S; Mohamed EM; Immadi S; Wu Z; Khan MA; Lu D; Nehete P; Rahman Z
Int J Pharm; 2021 Sep; 607():120889. PubMed ID: 34271151
[TBL] [Abstract][Full Text] [Related]
18. Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution.
Kevadiya BD; Woldstad C; Ottemann BM; Dash P; Sajja BR; Lamberty B; Morsey B; Kocher T; Dutta R; Bade AN; Liu Y; Callen SE; Fox HS; Byrareddy SN; McMillan JM; Bronich TK; Edagwa BJ; Boska MD; Gendelman HE
Theranostics; 2018; 8(1):256-276. PubMed ID: 29290806
[TBL] [Abstract][Full Text] [Related]
19. Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial.
Dooley KE; Kaplan R; Mwelase N; Grinsztejn B; Ticona E; Lacerda M; Sued O; Belonosova E; Ait-Khaled M; Angelis K; Brown D; Singh R; Talarico CL; Tenorio AR; Keegan MR; Aboud M;
Clin Infect Dis; 2020 Feb; 70(4):549-556. PubMed ID: 30918967
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Virological Outcomes of TB/HIV Coinfected Patients Treated With Dolutegravir-Based HIV Antiretroviral Regimens: Programmatic Experience From Botswana.
Modongo C; Wang Q; Dima M; Matsiri O; Kgwaadira B; Rankgoane-Pono G; Shin SS; Zetola NM
J Acquir Immune Defic Syndr; 2019 Oct; 82(2):111-115. PubMed ID: 31335593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
